CN101791338B - Medicament for resisting influenza and preparation method and application thereof - Google Patents
Medicament for resisting influenza and preparation method and application thereof Download PDFInfo
- Publication number
- CN101791338B CN101791338B CN2010101542184A CN201010154218A CN101791338B CN 101791338 B CN101791338 B CN 101791338B CN 2010101542184 A CN2010101542184 A CN 2010101542184A CN 201010154218 A CN201010154218 A CN 201010154218A CN 101791338 B CN101791338 B CN 101791338B
- Authority
- CN
- China
- Prior art keywords
- weight portion
- chinese medicine
- medicine composition
- influenza
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Abstract
The invention discloses a Chinese medicinal composition for resisting influenza in particular H1N1 influenza A, and a preparation method thereof. The Chinese medicinal composition for resisting the influenza is characterized by being prepared from the following raw materials in part by weight: 10 to 20 parts of baical skullcap root, 20 to 60 parts of giant knotweed rhizome, 5 to 10 parts of flos magnoliae liliflorae, and 5 to 10 parts of licorice. In order to further improve the curative effect, the Chinese medicinal medicament also comprises 15 to 30 parts of heartleaf houttuynia herb in part by weight. The medicament is prepared according to the following formula principles of: reasonable formula selection, clinical effectiveness, abundant resources, economical efficiency and practicability, and convenient popularization. Thus, the medicament reduces the types of used Chinese medicinal materials as much as possible, and under the condition that the influenza happens, particularly the H1N1 influenza A is pandemic, the Chinese medicinal composition can be popularized on a national scale to effectively prevent and control the spread of the influenza with the minimum economic cost and resource cost.
Description
Technical field
The present invention relates to a kind of influenza, especially the Chinese medicine composition of anti-H 1 N 1 influenza, medicine, its preparation method and application.
Background technology
Influenza A H1N1 influenza virus (InfluenzaA (H1N1) virus) is a kind of subtype influenza virus, also is one of human modal influenza (influenza), and some of them strain H1N1 virus can cause seasonal being very popular.Influenza A H1N1 (claiming H1N1 type swine flue in the past) epidemic situation is multinational outburst successively in America, spreads the whole world subsequently in by the end of March, 2009 to mid-April.According to World Health Organization's report, by on August 23rd, 2009, there were 209438 cases in the whole world, and at least 2185 people are dead.
It is reported that the production capacity of China's influenza A H1N1 vaccine can only cover national about 5% population to the end of the year in 2009.The influenza specific drug of having reported (like this its Wei difficult to understand) also occurs Drug resistance in the whole world to influenza A H1N1 influenza virus.Simultaneously, influenza A H1N1 influenza virus variation probability surpasses HIV, and the toxicity of the influenza A H1N1 influenza virus after the variation maybe be bigger, and currently available vaccines, existing vaccines and targeting medicine might all lose efficacy.
Therefore, the newtype drug of developing a kind of effective control influenza A H1N1 becomes important and urgent.
Summary of the invention
The present invention combines traditional Chinese medicine theory with modern molecular biology and drug design method; From the proteinic construction features of influenza A H1N1 influenza virus; Utilization modern structure biology, bioinformatics, Chemoinformatics; Strictly derive the pharmacophore of anti-influenza A H 1 N 1 virus molecule, derive the active component molecular structure group of corresponding Chinese medicine anti-influenza A H 1 N 1 virus, according to this molecular structure group by this type pharmacophore; Utilization world conventional medicament patent database, Chinese medicine structural database, Chinese medicine medical material-prescription-activity-chemical constituent integrated database; Derive the Chinese crude drug group that contains molecular structure group, again according to this Chinese crude drug group data, from the derive Chinese medicine composition of the special reply influenza A H1N1 influenza virus that makes new advances of the Chinese medicinal formulae data base of magnanimity.This compositions meets the medical knowledge of the traditional Chinese medical science fully through the analysis of Traditional Chinese Medicine experts.
An object of the present invention is to provide a kind of influenza Chinese medicine composition, it adopts following bulk drugs to process: Radix Scutellariae 10-20 weight portion, Rhizoma Polygoni Cuspidati 20-60 weight portion, Flos Magnoliae 5-10 weight portion, Radix Glycyrrhizae 5-10 weight portion.
In a preferred scheme, the consumption of Radix Scutellariae can be the 12-18 weight portion, for example the 12-16 weight portion.
In another preferred scheme, the consumption of Rhizoma Polygoni Cuspidati can be the 20-50 weight portion, for example 24-45 weight portion, particularly 25-40 weight portion.
In another preferred scheme, the consumption of Flos Magnoliae can be the 5-9 weight portion, for example 5-8 weight portion, particularly 5-7 weight portion.
In another preferred scheme, the consumption of Radix Glycyrrhizae can be the 5-9 weight portion, for example 5-8 weight portion, particularly 5-7 weight portion.
More preferably, also can comprise Herba Houttuyniae 15-30 weight portion in this Chinese medicine composition, for example 18-25 weight portion or 15-20 weight portion.
Second purpose of the present invention provided a kind of pharmaceutical preparation, wherein comprises Chinese medicine composition of the present invention or its activity extract and pharmaceutically suitable carrier.Said preparation can be the various dosage forms of using in the pharmaceutical field, for example tablet, capsule, oral liquid etc.
The 3rd purpose of the present invention provided the method for preparing of said Chinese medicine composition and pharmaceutical preparation.
The 4th purpose of the present invention provides said Chinese medicine composition or its pharmaceutical preparation is perhaps treated the application in the individual influenza, particularly anti-H 1 N 1 influenza medicine in the preparation prevention.The individuality here can comprise people, Canis familiaris L., cat, horse, pig or monkey.
The present invention is according to following prescription principle: reasonable, clinical effective, the aboundresources in choosing side, economical and practical, be convenient to popularization.Therefore, reduce the kind of employed Chinese crude drug, if influenza takes place as far as possible; Especially under the extensive popular situation of influenza A H1N1; The present invention can popularize in China, with the economic cost and the Resources Consumption of minimum, prevents and treats spreading of influenza effectively.
In the present invention, raw medicinal material is the form that extensively adopts in this area, and it can be through the method production of knowing in this area.For example; Radix Scutellariae (Scutellaria baicalensis Georgi), Rhizoma Polygoni Cuspidati (Polygonum cuspidatum Sieb.et Eucc), Flos Magnoliae (Magnoliabiondii); Radix Glycyrrhizae (Radix glycyrrhiza), Herba Houttuyniae (Houttuynia cordata Thumb)
Influenza Chinese medicine composition of the present invention can adopt the method preparation of knowing in this area; Be ground into fine powder after for example each crude drug being ground into behind the fine powder proportional mixing or proportional mixing; Also can with each crude drug adopt solvent to extract respectively and proportional mixing or proportional mixing after adopt solvent to extract to prepare; For example process filtrating, extractum or dried cream powder, the example of solvent comprises water and/or ethanol.
Can further adopt this area conventional method that Chinese medicine composition of the present invention is processed various clinical acceptable forms with pharmaceutically suitable carrier on this basis; Be pharmaceutical preparation of the present invention; For example prepare through Chinese medicine composition of the present invention is mixed with pharmaceutically suitable carrier, pharmaceutical preparation includes but not limited to: micropill, oral liquid, granule, powder, capsule, tablet, drop pill or decoction.Tablet can comprise coated tablet or buccal tablet
The effect of Chinese medicine composition of the present invention: heat-clearing and toxic substances removing, lung heat clearing is induced sweat.
The side separates: the Radix Scutellariae bitter cold, and clearing away heat and expelling pathogen in the exterior, Herba Houttuyniae is hot cold, clearing away lung-heat to relieve cough, two medicines are all gone into lung meridian, are monarch drug; The Rhizoma Polygoni Cuspidati bitter cold is gone into lung meridian, and the principal drug assistance lung heat clearing is ministerial drug; The hot temperature of Flos Magnoliae, clearing the nasal passage, antiallergic prevents that other drug from crossing cold impairing the lung because of the property of medicine, is adjuvant drug; Radix Glycyrrhizae is sweet flat, expelling phlegm for arresting cough, and coordinating the actions of various ingredients in a prescription is messenger drug.Said medicine is all gone into lung meridian.Full side " monarch " is reasonably combined, plays heat-clearing and toxic substances removing, the expelling pathogenic wind from the body surface effect.
In addition, modern study shows that Radix Scutellariae has inhibitory action to streptococcus pneumoniae, influenza virus PR8 strain etc.; Herba Houttuyniae has inhibitory action to streptococcus pneumoniae, and can relieving cough and diminishing inflammation, improve phagocytic activity of leukocytes; Rhizoma Polygoni Cuspidati has inhibitory action to staphylococcus aureus etc., and can spasmolytic relieving asthma, leukocyte increasing; Flos Magnoliae has inhibitory action to various pathogens, and can antiallergic, promote the rheuminess thing to absorb; Radix Glycyrrhizae has the effect similar with glucocorticoid, and antiinflammatory, antiallergic, antitussive effect are arranged.
Chinese medicine composition of the present invention had both met authoritative database informatics analysis report, met the traditional Chinese medical science " principle-method-recipe-medicines " principle and clinical efficacy rule again.Radix Scutellariae, Herba Houttuyniae, Rhizoma Polygoni Cuspidati are the preferred medicines of high frequency that information retrieval provides, the Flos Magnoliae antiallergic, and Radix Glycyrrhizae has hormone-like effect, again can clearing away lung-heat to relieve cough.
In the present invention, pharmaceutical carrier includes but not limited to diluent, excipient (like water etc.); Filler (like starch, sucrose etc.); Binding agent (like cellulose derivative, alginate, gelatin or polyvinylpyrrolidone); Wetting agent (like glycerol); Disintegrating agent (like agar, calcium carbonate or sodium bicarbonate); Absorption enhancer (like quaternary ammonium compound); Surfactant (like hexadecanol); Absorb carrier (like Kaolin and soap clay); Lubricant (like Pulvis Talci, calcium stearate or Polyethylene Glycol etc.).Can add other adjuvant such as flavouring agent, sweeting agent (like sucrose) etc. in addition as required.
Compositions of the present invention can administered through oral, snuffing is gone into or parenteral mode administration, so that be applicable to the patient who needs this treatment.Be used for when oral, can be made into conventional solid preparation such as tablet, powder, granule, capsule etc., perhaps process liquid preparation such as water and oil suspension or other liquid preparation such as syrup etc.When being used for parenteral, can be made into solution, water or the oiliness suspensoid etc. of injection.Preferred form is tablet, capsule or injection.
In one embodiment, pharmaceutical preparation of the present invention prepares through following method: 1) the various crude drug in the said Chinese medicine composition are processed extract such as granule respectively, perhaps two or more crude drug are wherein processed extract such as granule together; 2) various extracts of proportional mixing randomly; 3) said mixture and pharmaceutically suitable carrier is combined.
Medicine of the present invention can be used for prevention or treats various influenzas, comprises influenza A H1N1.In one embodiment; The invention provides the method for a kind of prevention or treatment influenza, especially influenza A H1N1, comprising with prevention or treatment effective dose to suffering from or the individuality of risky trouble influenza, especially influenza A H1N1 is used pharmaceutical preparation of the present invention.Suitable consumption is that those of ordinary skills can confirm according to routine techniques easily, 0.22 gram/kg body weight for example, preferred 0.44 gram/kg body weight.In the present invention, " individuality " comprises various animals, for example birds, mammals, especially people, Canis familiaris L., cat, horse, pig, monkey etc.In the present invention, " using " comprises any suitable way, for example oral administration, sublingual administration, nasal mucosa administration, intravenous administration etc.
The specific embodiment
Influenza compositions embodiment of the present invention is following:
The method for preparing of embodiment 1-4:
1) amount that converts by weight portion shown in the above form takes by weighing Herba Houttuyniae, suitably pulverizes, and sieves, and places volatile oil extractor, adds 10 times of water gagings, behind the warm macerating 0.5h, and heating, steam distillation is collected distillate behind the 4h.Distillate is with extracted with diethyl ether 3 times, and extract adds anhydrous sodium sulfate drying 24h after-filtration, and filtrating is flung to ether with Rotary Evaporators, collects volatile oil, and volatile oil presents pistac.Residue decocts twice again, adds the water of 5 times of amounts at every turn, decocts 1h, filters, and filtrating merges subsequent use, and residue discards.
2) amount that converts by weight portion shown in the above form takes by weighing Radix Scutellariae, Rhizoma Polygoni Cuspidati, Flos Magnoliae and Radix Glycyrrhizae.Suitably pulverize, sieve, decocte with water 2 times adds 5 times of water gagings at every turn, decocts 2h, extracting liquid filtering at every turn; Merging filtrate adds the aqueous solution after Herba Houttuyniae extracts volatile oil simultaneously, is concentrated into 10g medical material/ml, adds 95% ethanol, and the limit edged stirs; To determining alcohol 80%, cold preservation was placed 24 hours, filtered, and filtrate recycling ethanol is to not having alcohol flavor, spray drying then; Herba Houttuyniae volatile oil adds an amount of dissolve with ethanol, sprays in the fine powder, and is evenly mixed, the powder that promptly gets dry extract, and paste-forming rate is controlled at 5%.
3) preparation process: dried cream powder 1.5 weight portions, starch 1 weight portion.Dried cream powder and starch is evenly mixed, add 85% alcohol granulation, 60-65 ℃ of oven dry is with 16 eye mesh screen granulate.
The method for preparing of embodiment 5:
1) amount that converts by weight portion shown in the above form takes by weighing Radix Scutellariae, Rhizoma Polygoni Cuspidati, Flos Magnoliae and Radix Glycyrrhizae.Suitably pulverize, sieve, add 10 times of water gagings, decoct 2 times, each 2h, extracting liquid filtering, merging filtrate, every milliliter is equivalent to 0.1 gram crude drug.
3) preparation process: in the filtrating that merges, add suitable amount of sucrose, packing then, promptly gets oral formulations by 10 milliliters every bottle.
Experimental example
One, materials and methods
1, virus
Influenza virus Mus lung adapted strain FM1 (A (H 1 N 1) virus) is provided by Virology Inst., Chinese Academy of Preventive Medical Science.Embryo Gallus domesticus goes down to posterity, and detects packing ,-80 ℃ of preservations in BSL-3 (three grades of the biocontainment laboratories) laboratory.
2, laboratory animal
72 of BALB/c mouse body weight 20～22g available from Beijing Vital River Experimental Animals Technology Co., Ltd., raise under animal housing of this institute cleaning level condition.
3, experiment medicine
Experimental drug is the medicine of embodiment 1,2 and 5.Positive control drug is commercially available ribavirin (0.15g that is grown up a time, 3 times on the one, logotype 7 days) SFDA Recognized Standards (Sichuan hundred sharp Pharmaceutical lot:081017).
4, experimental technique
It is that blank group, infection group and viral infection group, positive drug contrast are (according to 0.15g of adult that mice is divided into 6 groups at random; 3 times on the one conversions), the medicine of embodiment 1, the medicine of embodiment 2 and the medicine (0.04g/20g crude drug) of embodiment 5; Embodiment 1 needs to grind and add an amount of distilled water to become suspension with 2 drug study is preceding, and every group of 10-12 only.Infect and to begin gastric infusion the previous day, 0.4ml/ is (0.1g crude drug/ml), 1 time/day, successive administration 5 days only.Blank group, infection group and viral infection group give the equal-volume distilled water.Zoogenetic infection virus: every mice carries out collunarium with influenza virus Mus lung adapted strain FM1 and infects after the slight anesthesia of ether.Except that the normal control group, all the other each groups all infect FM1, and 50ul/ is (10 LD only
50).
After the 5th day of administration, after mice is weighed, slightly anaesthetize, lung tissue is got in blood-letting, weighs.Calculate lung index (lung exponential quantity=100 * lung weight/body weight, SFDA announces formula).Carry out statistical procedures, respectively organize the exponential difference of lung.
5, date processing and statistical method
Data are expression with
, adopts the SAS software data processing.
Two, experimental result
1. respectively organize lung exponential experiment data
Each experimental group lung exponent data of table 1
2. statistical analysis between each is organized
Lung exponential quantity=100 * lung weight/body weight.The lung exponential quantity is big more, and the expression pneumonia is serious more.Obtain and respectively organize exponential average of lung and SD, the comparable group differences carries out statistical analysis.
Table 2 medicine is to the preventive and therapeutic effect of H1N1 mice influenza
Annotate: ▲ comparing with infection group and viral infection group, △ and normal control group are relatively
Experimental result by table 1 and 2 shows that medicine of the present invention presents certain dose-effect characteristic to H1N1, shows to have preventive and therapeutic effect; It is better to show also that in addition the present invention comprises the medication effect of Herba Houttuyniae, is preferred scheme.
Claims (18)
1. anti-H 1 N 1 influenza Chinese medicine composition, it is to adopt following bulk drugs to process: Radix Scutellariae 10-20 weight portion, Rhizoma Polygoni Cuspidati 20-60 weight, Flos Magnoliae 5-10 weight portion and Radix Glycyrrhizae 5-10 weight portion.
2. anti-H 1 N 1 influenza Chinese medicine composition, it is to adopt following bulk drugs to process: Radix Scutellariae 10-20 weight portion, Rhizoma Polygoni Cuspidati 20-60 weight, Flos Magnoliae 5-10 weight portion, Radix Glycyrrhizae 5-10 weight portion and Herba Houttuyniae 15-30 weight portion.
3. claim 1 or arbitrary Chinese medicine composition of 2, wherein Radix Scutellariae is the 12-16 weight portion.
4. the Chinese medicine composition of claim 3, wherein Radix Scutellariae is the 12-18 weight portion.
5. claim 1 or arbitrary Chinese medicine composition of 2, wherein Rhizoma Polygoni Cuspidati is the 20-50 weight portion.
6. the Chinese medicine composition of claim 5, wherein Rhizoma Polygoni Cuspidati is the 24-45 weight portion.
7. claim 1 or arbitrary Chinese medicine composition of 2, wherein Flos Magnoliae is the 5-9 weight portion.
8. the Chinese medicine composition of claim 7, wherein Flos Magnoliae is the 5-8 weight portion.
9. claim 1 or arbitrary Chinese medicine composition of 2, wherein Radix Glycyrrhizae is the 5-9 weight portion
10. the Chinese medicine composition of claim 9, wherein Radix Glycyrrhizae is the 5-8 weight portion.
11. the Chinese medicine composition of claim 2, wherein said Herba Houttuyniae are the 18-25 weight portion.
12. a pharmaceutical preparation, it comprises each Chinese medicine composition and pharmaceutically suitable carrier of claim 1-11.
13. the pharmaceutical preparation of claim 12, said preparation are micropill, oral liquid, granule, powder, capsule, tablet, drop pill or decoction form.
14. the pharmaceutical preparation of claim 13, wherein tablet is coated tablet or buccal tablet.
15. method for preparing claim 12 pharmaceutical preparation; It is characterized in that: each the raw medicinal material of Chinese medicine composition of claim 1-11 is ground into powder or each the raw medicinal material of Chinese medicine composition of claim 1-11 is obtained activity extract with solvent extraction, then said powder or activity extract are fully mixed with pharmaceutically suitable carrier.
16. the method for claim 15 wherein adopts water as solvent, extracts said raw medicinal material and prepares activity extract according to the ratio of 10 parts of water of 1 part of medicine.
17. each each pharmaceutical preparation of Chinese medicine composition or claim 12-14 of claim 1-11 is in the preparation prevention or treat the application in the medicine of individual influenza A H1N1.
18. the application of claim 17, wherein said individuality are people, Canis familiaris L., cat, horse, pig or monkey.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101542184A CN101791338B (en) | 2010-04-23 | 2010-04-23 | Medicament for resisting influenza and preparation method and application thereof |
| PCT/CN2010/001734 WO2011130892A1 (en) | 2010-04-23 | 2010-11-01 | Traditional chinese medicinal composition for treating influenza and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101542184A CN101791338B (en) | 2010-04-23 | 2010-04-23 | Medicament for resisting influenza and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101791338A CN101791338A (en) | 2010-08-04 |
| CN101791338B true CN101791338B (en) | 2012-04-25 |
Family
ID=42584397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101542184A Expired - Fee Related CN101791338B (en) | 2010-04-23 | 2010-04-23 | Medicament for resisting influenza and preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101791338B (en) |
| WO (1) | WO2011130892A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011063753A1 (en) * | 2009-11-26 | 2011-06-03 | 桂林商源植物制品有限公司 | Traditional chinese medicine composition for treating oral ulcer and tumor, preparation method and use thereof |
| CN101791338B (en) * | 2010-04-23 | 2012-04-25 | 苏州东方楷模医药科技有限公司 | Medicament for resisting influenza and preparation method and application thereof |
| CN103191291B (en) * | 2013-04-09 | 2014-09-03 | 王金磊 | Traditional Chinese medicine composition for treating viral myocarditis |
| EP4293141A1 (en) | 2022-06-13 | 2023-12-20 | Dubai Aluminium PJSC | Anode servicing assembly for an aluminium electrolysis plant, and methods for operating the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1048176C (en) * | 1995-07-31 | 2000-01-12 | 李俊华 | Face-nurishing acne-diminishing capsule |
| CN1167445C (en) * | 2001-08-15 | 2004-09-22 | 李咸珠 | Chinese medicine for treating rhinitis and nasosinusitis |
| CN1589852A (en) * | 2003-08-28 | 2005-03-09 | 昆明滇虹药业有限公司 | External use nose drop agent for treating common cold and its preparation method |
| CN1274327C (en) * | 2003-08-30 | 2006-09-13 | 昆明滇虹药业有限公司 | Nose drops agent for treating common cold and its preparation method |
| CN101791338B (en) * | 2010-04-23 | 2012-04-25 | 苏州东方楷模医药科技有限公司 | Medicament for resisting influenza and preparation method and application thereof |
-
2010
- 2010-04-23 CN CN2010101542184A patent/CN101791338B/en not_active Expired - Fee Related
- 2010-11-01 WO PCT/CN2010/001734 patent/WO2011130892A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| CN101791338A (en) | 2010-08-04 |
| WO2011130892A1 (en) | 2011-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102085311B (en) | Traditional Chinese medicinal composition for preventing or treating common cold and/or flu, method for preparing same and application thereof | |
| CN101049424B (en) | Medication for treating infection in respiratory system | |
| CN101933991B (en) | Analgesic and anti-inflammatory medicament and preparation method thereof | |
| CN100522212C (en) | Traditional Chinese medicine composition for treating depression and its preparing method | |
| CN101791338B (en) | Medicament for resisting influenza and preparation method and application thereof | |
| CN1210047C (en) | Medicine for treating common cold and preparation method | |
| CN101468089B (en) | Chinese medicinal composition for diffusing lung, relieving exterior syndrome, suppressing cough and reducing phlegm and preparation method thereof | |
| CN111202827A (en) | Chinese medicine for preventing influenza, SARS, bird flu and new coronary pneumonia | |
| CN1969997A (en) | Antivirus compound formulation, preparation process, quality control method and use thereof | |
| CN105343481A (en) | Application of influenza treating medicine composition in preparation of antiviral medicine | |
| CN104958419B (en) | The careless capsule for clearing away heat of gold and manufacture craft | |
| CN102198175B (en) | Chinese medicine composition | |
| CN101390970B (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN103356728B (en) | Pharmaceutical composition, preparation method thereof, preparations thereof and application thereof | |
| CN101088533A (en) | Antiviral Chinese medicine prepn and its prepn process, quality control method and application | |
| CN110193061A (en) | A kind of preparation and application of the Chinese herbal granules treating or preventing influenza virus of children infection | |
| CN105535135B (en) | A kind of Chinese medicine composition with resisiting influenza virus effect and preparation method thereof and purposes | |
| CN1969871A (en) | Antivirus compound formulation, preparation process, quality control method and use thereof | |
| CN101912442A (en) | Micro-enema for treating upper respiratory track infection and preparation method thereof | |
| CN102100752B (en) | Medicinal composition for resisting influenza virus, preparation method thereof and application thereof | |
| CN100358530C (en) | Medicine prepn for treating cerebral apoplexy and its prepn | |
| CN1438017A (en) | Medicine for treating common cold and preparation method | |
| CN105641168A (en) | Medicine for treating viral hepatitis B and viral hepatitis C and preparation method of medicine | |
| CN102274393B (en) | Medicament for treating cold and preparation method thereof | |
| CN102335248A (en) | Antivirus traditional Chinese medicinal composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 405, A3, building 404 and 99, AI Yan Road, Suzhou Industrial Park, Jiangsu, Suzhou, 215123 Applicant after: KMS Meditech, Inc. Address before: Xinghu street Suzhou Park 215125 Jiangsu province No. 218 BioBAY A3 No. 201-C Applicant before: KMS Meditech, Inc. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120425 Termination date: 20200423 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |